论文部分内容阅读
目的 评估卡维地洛治疗轻中度稳定性慢性心力衰竭的临床耐受性和安全性。方法4 82例符合轻中度慢性心衰标准的患者在常规治疗后 ,病情基本稳定的基础上加用卡维地洛。卡维地洛从小剂量 3 12 5mg每日两次开始 ,每两周递增一次 ,直至靶剂量 2 5mg每天 2次或最大耐受剂量。治疗前后分别对心功能 (NYHA)分级、心衰评分、血压、心率等体征及实验室 (血常规 ,肝肾功能及心电图等 )检查进行检测 ,评判疗效、耐受性及安全性。结果 用卡维地洛治疗后心功能明显改善 ,心衰评分下降 ,提示生活质量改善 ,同时不良反应少 ,安全性好。 6 0 %的患者可以达到推荐靶剂量。结论 卡维地洛治疗轻中度慢性稳定性心衰耐受性和安全性良好。
Objective To evaluate the clinical tolerability and safety of carvedilol in the treatment of mild to moderate stable chronic heart failure. Methods Four hundred and eighty-two patients who met the criteria of mild to moderate chronic heart failure were treated with carvedilol on the basis of the basically stable condition after routine treatment. Carvedilol starts at a low dose of 3125 mg twice daily, increasing every two weeks until the target dose is 25 mg twice daily or the maximum tolerated dose. Before and after treatment, NYHA classification, heart failure index, blood pressure, heart rate and other signs and laboratory tests (blood, liver and kidney function and electrocardiogram, etc.) were tested to evaluate the efficacy, tolerability and safety. Results After treatment with carvedilol, heart function improved significantly, heart failure score decreased, suggesting that the quality of life improved with fewer adverse reactions, good safety. 60% of patients can reach the recommended target dose. Conclusion Carvedilol is good and safe for mild to moderate chronic stable heart failure.